Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma

Papewalis, Claudia; Fassnacht, Martin; Willenberg, Holger S.; Domberg, Julia; Fenk, Roland; Rohr, Ulrich-Peter; Schinner, Sven; Bornstein, Stefan R.; Scherbaum, Werner A.; Schott, M.

doi:10.1111/j.1365-2265.2006.02576.x

Cited by 20 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, these data await confirmation by others. In our studies, we were able to demonstrate that DCs might be fused with the tumour cells shown to have high efficacy rates in adrenal carcinoma cells (Papewalis et al 2006). Using electron microscopy, we could demonstrate viable cells indicated by intact basal membranes.…”

Section: Loading Methods In Tumour Antigensmentioning

confidence: 54%

See 1 more Smart Citation

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

Schott

2006

Endocr Relat Cancer

Self Cite

View full text Add to dashboard Cite

Dendritic cells (DCs) are highly efficient antigen-presenting cells in the immune system with the potential to regulate the system and induce a cytotoxic T-cell response. As a proof of principle, a multitude of animal and human studies has demonstrated that immunization with antigen-loaded DCs may lead to anti-tumour immune responses with tumour regression and rejection of cancer. The identification of tumour antigens that can be recognized by T lymphocytes has facilitated the development of new protocols and enabled immunologists to monitor immune responses. However, to date, long-term clinical effects on larger numbers of cancer patients are missing, and there is no generally accepted DC generation or activation protocol. This review will focus on the most important findings on the role of DCs within the immune system and how to generate and activate these cells in order to induce cytotoxic immunity in non-endocrine and endocrine malignancies. Recently, we and other researchers reported on DC vaccinations in patients with endocrine malignancies mainly in metastasized medullary thyroid carcinoma resulting in tumourspecific immunity and partial clinical responses in some cases. Based on these and other in vitro data, new DC vaccination protocols for the treatment of patients with endocrine tumours have now been conducted.

show abstract

Section: Loading Methods In Tumour Antigensmentioning

confidence: 54%

“…Recently, we also performed a DC vaccination trial in two patients with adrenocortical carcinoma (Papewalis et al 2006). Within this study, the mature DCs were generated as previously described (Schuler-Thurner et al 2002).…”

Section: Immunotherapy In Non-thyroid Endocrine Malignanciesmentioning

confidence: 99%

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

Schott

2006

Endocr Relat Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mitotane is the only FDA-approved cytotoxic treatment, which has minimal effects on 5-year survival rates (Aufforth & Nilubol 2014). Immunotherapy approaches have not been successful due to the secretion of immunosuppressive glucocorticoids, the lack of known ACC-tumour-specific antigens and insufficient knowledge of the ACC immunosuppressive microenvironment (Papewalis et al 2006). In addition, adrenal masses are often clinically unapparent and with few reliable markers, histological differentiation of benign and malignant lesions remains difficult (Mansmann et al 2004).…”

Section: Adrenalcortical Tumourmentioning

confidence: 99%

The role of the tumour microenvironment in immunotherapy

Gasser

Lim

Cheung

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Recent success in immunomodulating strategies in lung cancer and melanoma has prompted much enthusiasm in their potential to treat other advanced solid malignancies. However, their applications have shown variable success and are even ineffective against some tumours. The efficiency of immunotherapies relies on an immunogenic tumour microenvironment. The current field of cancer immunology has focused on understanding the interaction of cancer and host immune cells to break the state of immune tolerance and explain how molecular patterns of cytokines and chemokines affect tumour progression. Here, we review our current knowledge of how inherent properties of tumours and their different tumour microenvironments affect therapeutic outcome. We also discuss insights into recent multimodal therapeutic approaches that target tumour immune evasion and suppression to restore anti-tumour immunity.

show abstract

“…The rationale of immunotherapy is based on the stimulation of the immune system against antigens of the neoplastic cell. The attempt to -stimulate the immune system‖ with autologous dendritic cells of two patients with ACC metastatic secreting induced antigen-specific Th1 immunity did not produce any clinical benefit [176]. Probably, the main limitation in this type of approach consists in the identification of a specific tumor antigen.…”

Section: Targeted Therapiesmentioning

confidence: 99%

Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

Stigliano

Chiodini

Giordano

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma

Abstract: Our data demonstrate that autologous dendritic cells induce antigen-specific Th1 immunity in adrenocortical carcinoma. The clinical outcome, however, was not improved in the patients studied here.

Cited by 20 publications

References 43 publications

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

The role of the tumour microenvironment in immunotherapy

Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

Contact Info

Product

Resources

About